Tumor Necrosis Factor Blocker [EPC]

767612 reported adverse events

Drugs of this class: ETANERCEPT INFLIXIMAB GOLIMUMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 89752
1 INJECTION SITE PAIN 57278
2 ARTHRALGIA 49733
3 PAIN 44922
4 RHEUMATOID ARTHRITIS 44447
5 INJECTION SITE ERYTHEMA 41353
6 OFF LABEL USE 39948
7 FATIGUE 33371
8 HEADACHE 27686
9 PSORIASIS 27470
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 INJECTION SITE RECALL REACTION 481 0.9776
1 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 284 0.9759
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 2404 0.9307
3 SWOLLEN JOINT COUNT INCREASED 451 0.8826
4 RHEUMATOID FACTOR POSITIVE 2229 0.8677
5 RHEUMATIC FEVER 580 0.8657
6 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1514 0.8646
7 PEMPHIGUS 4576 0.8525
8 C-REACTIVE PROTEIN ABNORMAL 2387 0.8037
9 HAND DEFORMITY 4764 0.7630
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]